Literature DB >> 15502830

Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier.

Fuan Wang1, Yiyue Ma, John W Barrett, Xiujuan Gao, Joy Loh, Erik Barton, Herbert W Virgin, Grant McFadden.   

Abstract

Myxoma virus, a member of the poxvirus family, causes lethal infection only in rabbits, but the mechanism underlying the strict myxoma virus species barrier is not known. Here we show that myxoma virus infection of primary mouse embryo fibroblasts elicited extracellular signal-regulated kinase (Erk) signaling, which was integrated to interferon regulatory factor 3 activation and type I interferon induction. We further show that Erk inactivation or disruption of interferon signaling mediated by the transcription factor STAT1 broke the cellular blockade to myxoma virus multiplication. Moreover, STAT1 deficiency rendered mice highly susceptible to lethal myxoma virus infection. Thus, the Erk-interferon-STAT1 signaling cascade elicited by myxoma virus in nonpermissive primary mouse embryo fibroblasts mediates an innate cellular barrier to poxvirus infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502830     DOI: 10.1038/ni1132

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  89 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Adaptive changes in alphavirus mRNA translation allowed colonization of vertebrate hosts.

Authors:  Iván Ventoso
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

3.  Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway.

Authors:  Peihong Dai; Hua Cao; Taha Merghoub; Francesca Avogadri; Weiyi Wang; Tanvi Parikh; Chee-Mun Fang; Paula M Pitha; Katherine A Fitzgerald; Masmudur M Rahman; Grant McFadden; Xiaoyu Hu; Alan N Houghton; Stewart Shuman; Liang Deng
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

5.  Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence.

Authors:  Brian C Keller; Brenda L Fredericksen; Melanie A Samuel; Richard E Mock; Peter W Mason; Michael S Diamond; Michael Gale
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 6.  Viruses as anticancer drugs.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

Review 7.  Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation.

Authors:  Matthew Frieman; Ralph Baric
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

8.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

9.  Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized.

Authors:  Fuan Wang; John W Barrett; Yiyue Ma; Gregory A Dekaban; Grant McFadden
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Filamin B serves as a molecular scaffold for type I interferon-induced c-Jun NH2-terminal kinase signaling pathway.

Authors:  Young Joo Jeon; Joon Seok Choi; Jung Yun Lee; Kyung Ryun Yu; Seung Hyeun Ka; Yongcheol Cho; Eui-Ju Choi; Sung Hee Baek; Jae Hong Seol; Dongeun Park; Ok Sun Bang; Chin Ha Chung
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.